THU0156 Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials
Authors: C. Han, E. Keystone, R. Fleischmann, J. Smolen, E.L. Matteson, P. Emery, M. Genovese, T. Gathany, E.C. Hsia
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To assess the impact of golimumab (GLM) on physical function and employability in patients with rheumatoid arthritis (RA) with various prior treatment histories, after 5 years of therapy. <h3>Methods</h3> The efficacy and safety of GLM were assessed in methotrexate (MTX)-naïve RA patients (GO-BEFORE, N=637), patients with inadequate response to MTX (GO-FORWARD, N=444), and patients previously treated with TNF-inhibitors (TNFi, GO-AFTER, N=445). Patients with active RA were randomized to placebo (PBO), GLM 100mg+PBO (GO-BEFORE and GO-FORWARD), or GLM (50 or 100mg), q4w. Patients in GO-BEFORE and GO-FORWARD could receive concomitant MTX or no MTX and crossed-over to GLM after wk24 (GO-FORWARD) OR wk52 (GO-BEFORE), while patients in GO-AFTER were on background (with or without) MTX and crossed-over to GLM after wk24. Clinical remission was defined as DAS28 (ESR) &lt;2.6. Physical function was measured using Health Assessment Questionnaire (HAQ) and employability was defined as being employed or being able to work if job was available (Yes/No). 5 year data were presented by 3 patient populations. <h3>Results</h3> At baseline, the percent of patients with disability (HAQ-DI score &gt;0.5) in each of 3 RA populations were 90.9% in patients who were MTX-naïve, 87.6% in patients who were MTX-inadequate responders and 92.3% in patients who were TNFi-experienced. Among the analyzed patient population for employability (not retired and age&lt;65 years), the percent of patients unemployable due to their RA at baseline were 9% in MTX-naïve patients, 8.1% in MTX-inadequate responders and 13.1% in TNF-experienced patients. After treatment with GLM, among those who had disability at baseline, 46.8% of MTX-naive patients, 37.5% of MTX-inadequate responders and 27.5% of TNFi-experienced patients had no disability (HAQ-DI score≤0.5) at wk256; among patients unemployable at baseline, 29.5% of MTX-naive patients, 28.6% of MTX-inadequate responders and 5.4% of TNFi-experienced patients regained employability at wk256. Similar trends of better outcomes on disability and employability of MTX-naïve patients were observed among those who achieved remission at wk256: 65.1% in MTX- naive patients, 54.4% in MTX-inadequate responders and 53.1% in TNFi-experienced patients achieved no disability; and 73.3% in MTX-naive patients, 50% in MTX-inadequate responders and 50.0% in TNFi-experienced patients regained employability. <h3>Conclusions</h3> This analysis indicates that effective treatment at an early stage may result in reduction in disability and improvement in employability over the long-term. <h3>Disclosure of Interest</h3> : C. Han Employee of: Janssen Research &amp; Development, LLC., E. Keystone Grant/research support: Janssen Research &amp; Development, LLC., R. Fleischmann Grant/research support: Janssen Research &amp; Development, LLC., J. Smolen Grant/research support: Janssen Research &amp; Development, LLC., E. Matteson: None declared, P. Emery Grant/research support: Janssen Research &amp; Development, LLC., M. Genovese Grant/research support: Janssen Research &amp; Development, LLC., T. Gathany Employee of: Johnson &amp; Johnson Pharmaceutical Services, LLC, E. Hsia Employee of: Janssen Research &amp; Development, LLC. <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2535